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ABSTRACT
Introduction: The worldwide spread of antimicrobial
resistance is now recognised as a global public health
threat. Owing to the geographical heterogeneity,
complexity and continuously evolving dynamics of
resistant organisms and genes, surveillance is a key
tool for understanding, measuring and informing
actions in the fight against this problem. To date there
is no harmonisation of key indicators or of
methodologies used to obtain them.
Methods and analysis: The main objective of this
project is to systematically review and analyse the
current publicly available surveillance activities on
antimicrobial resistance and healthcare-associated
infections in Europe. Eligible activities are those
endorsed by regional, national or transnational health
organisations and scientific societies providing data on
a periodic basis. Grey and peer-reviewed literature will
be searched with no language restrictions. Three
independent reviewers will perform a two-step
selection process using a previously piloted, tailored
electronic data extraction form. Descriptive summaries
and tables of all relevant findings will be performed
and reported according to PRISMA guidelines.
Ethics and dissemination: We did not seek ethical
approval for this study because the data to be collected
are not linked to individuals. Data will be presented at
international conferences and published in peer-
reviewed journals.
Trial registration number: CRD42016033867.
INTRODUCTION
The worldwide spread of antimicrobial resist-
ance (AMR) is now recognised as a global
public health threat.1 2 Owing to the geograph-
ical heterogeneity, complexity and continuously
evolving dynamics of resistant organisms and
genes, surveillance is a key tool for understand-
ing, measuring and informing actions in the
ﬁght against this problem. Indeed, surveillance
systems for AMR have been developed by most
national health systems and transnational
organisations.3–5 Adequate characterisation of
the burden of disease caused by resistant patho-
gens, their impact on patient outcomes and the
areas and patient populations with the highest
incidences are critical for identifying medical
needs, establishing treatment protocols and
efﬁciency of design for randomised controlled
trials. The situation with healthcare-associated
infections (HAI), which are often closely
associated with AMR, is similar.
Strengths and limitations of this study
▪ Wide scope search strategy including peer-
reviewed and grey literature.
▪ No language restriction and study protocol
designed by a multidisciplinary team within a
multinational collaborative consortium.
▪ Surveillance systems for which the methodology
is not publicly available will be missed.
▪ The review will rely on the data provided in the
accessible sources, while some surveillance
activities might have changed after their
publication.
▪ Despite following a carefully prepared search
strategy, some surveillance systems or specific
information from them may not be found.
However, this will indicate a problem in the
accessibility to the information.
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An important problem for the surveillance of AMR
and HAI is heterogeneity of the scope, focus, objectives,
methodology, resources and reporting across the differ-
ent regions and countries, despite the efforts of institu-
tions such as the European Centre for Disease
Prevention and Control (ECDC), Centers for Disease
Control and Prevention (CDC) or the WHO.3–5 The
ECDC conducted a comprehensive review of the current
situation and implications of HAIs across Europe; these
authors highlighted that while some progress has been
achieved in recent years, there are still substantial inter-
country and intracountry differences in surveillance
methods and concluded that greater emphasis be placed
on harmonisation.5
The objectives of SUSPIRE are to systematically review
and analyse the surveillance activities endorsed by
national or transnational health organisations and scien-
tiﬁc societies that are performed in the European Union
and European Economic Area (EU/EAA) and to
provide regular data on HAI and AMR. The ﬁnal object-
ive of this effort is to provide recommendations that can
be used for the harmonisation of surveillance systems.
METHODS
Eligibility criteria
SUSPIRE targets surveillance systems endorsed by
regional, national or transnational health organisations
or scientiﬁc societies in EU/EEA countries that are in
place for the purpose of providing regular data on AMR
and/or HAI.
Information sources and search strategy
A comprehensive search strategy for searching grey and
peer-reviewed literature will be performed until 30
November 2016, using the Google search engine for the
ﬁrst task, and combining the following terms in the local
languages of the various European countries or regions
(depending on whether the public health providers are
centralised/national or decentralised): ‘Antimicrobial
resistance’ AND/OR ‘Hospital-associated’ OR
‘Hospital-acquired’ OR ‘Nosocomial’ AND ‘Surveillance’
AND ‘epidemiology’ OR ‘prevalence’ OR ‘incidence’.
Sources of peer-reviewed literature to be searched
include: PubMed, Embase, Scopus (Elsevier Science)
and Web of Science (Thomson, ISI), using the same
subject headings (MeSH). A draft PubMed search strat-
egy is included in online supplementary appendix 1.
Articles available until 30 June 2016 will be included.
‘Zoonotic’ OR ‘food-borne’ OR ‘outbreak’ will be
excluded in all cases, and ‘human data’ will be imposed
on the search whenever possible.
We will also review the ofﬁcial health-related websites
of national and transnational health organisations and
scientiﬁc societies, such as the ECDC, WHO Europe,
regional and national European governments, and of
relevant scientiﬁc societies, such as ESCMID (European
Society of Clinical Microbiology and Infectious Diseases;
ISID (International Society for Infectious Diseases); IEA
(International Epidemiological Association); ESICM
(European Society of Intensive Care Medicine) or ERS
(European Respiratory Society), among others.
Additional data will be obtained from references in
retrieved articles and data provided by stakeholders fol-
lowing the request to complete the catalogue of surveil-
lance systems and reports on AMR and HAI.
Inclusion and exclusion criteria
The documents retrieved will be assessed for their
content and the inclusion and exclusion criteria shown
in box 1 applied for those documents to be ﬁnally
included in the review.
No language restrictions will apply; local experts, iden-
tiﬁed by the European Committee on Infection Control
(EUCIC) of the European Society of Clinical
Microbiology and Infectious Diseases, will be consulted.
Data management, selection process and data extraction
The literature search results will be uploaded to
EndNote X7 software. Two independent reviewers will
perform a two-step selection process. Titles and abstracts
(if available) of the retrieved documents will be initially
assessed and non-relevant documents excluded. The full
text of potentially eligible documents will then be
obtained and assessed for relevance or duplication
against predeﬁned selection criteria.
Data will be extracted independently by two reviewers,
using a tailored electronic data extraction form to be
piloted beforehand on a representative sample. The
Box 1 Eligibility criteria for surveillance systems
Inclusion criteria
▸ European surveillance systems, or including European data
▸ Epidemiological surveillance studies collecting data for at least
five consecutive years from three or more sites, and with at
least one data collection year within the last 10 years
▸ Promoted or endorsed by national or transnational health
organisations and scientific societies
▸ Providing, or with the intention to provide, data on a periodic
basis
▸ Providing data on at least one of the following: objective,
scope (eg, hospital and healthcare-associated infections/patho-
gens), design and methodological issues
▸ Published scientific and ‘grey’ literature
▸ Human data
▸ No age/language restriction
Exclusion criteria
▸ Animal, environmental or food data only
▸ Epidemiological studies or reports whose main objective is dif-
ferent from that of providing surveillance data
▸ Epidemiological studies or surveillance data promoted by
private companies
▸ Outbreak reports
▸ Systems that are ‘inactive’ (not providing any information) for
the last 10 years
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same core data will be extracted from systems and
studies including speciﬁc details about the following ele-
ments: programme, population, microbiology, method-
ology, quality indicators and data. A detailed list of
variables is presented in table 1.
Disagreements between reviewers will be resolved by
consultation with a third reviewer.
Quality assessment
There are several generic guidelines for evaluating
human public health surveillance, and these typically
include assessing a series of attributes, such as ﬂexibility,
acceptability and timeliness, using a combination of
quantitative and qualitative techniques. The quality of
the surveillance systems included in our review will be
assessed on the basis of the attributes recommended in
the Centres for Disease Prevention and Control guide-
lines for evaluating public health surveillance systems.6
The protocol was developed following the recently
released PRISMA-P guidelines, and the review will be
reported in accordance with the PRISMA statement.7
Data synthesis and descriptive analysis
The data synthesis phase will involve collating and sum-
marising the results in the form of a table that indicates
the core characteristics of the systems and studies: type
of activity, isolate source, population, phenotypes and
mechanisms of resistance, deﬁnitions of acquisition,
indicators and quality assessments. Frequency
distributions expressed as percentages (%) will be calcu-
lated for each variable and displayed graphically.
Analysis will be stratiﬁed by country, surveillance type
(system/study) and activity (HAI/AMR).
Dissemination
Data will be presented at international conferences and
published in peer-reviewed journals.
DISCUSSION
Following the original SENIC studies in the 1970s, sur-
veillance has been recognised as a key component of
quality assurance in general and of infection control in
particular.8 Since then, surveillance procedures and
systems have evolved in accordance with increased aware-
ness of the complexity and importance of HAIs as a
patient safety concern9 and the rise of AMR. Most coun-
tries started surveillance systems for HAIs during the
1980s and 1990s. A series of articles published in 2001
showed how heterogeneous the surveillance activities
performed in European countries at that time were.10
Over recent decades, the ECDC has been extraordinarily
active in working towards the homogenisation of deﬁni-
tions, procedures and systems developed.3 6 In 2008, the
ECDC conducted a review highlighting that there were
still signiﬁcant limitations to surveillance systems across
European countries.11 The aim of SUSPIRE is to provide
an update of the situation, with the additional purpose
of speciﬁcally evaluating particular aspects of the
Table 1 Summary list of variables collected
Core element Variable
Program System name & acronym*
Title & author/s name†
Location and magnitude
Status: Active/inactive* & completed/ongoing†
Coordinating organization and resources
Focus: Type of activity (HAI, AMR)
Link: System website/journal article
Update year
Population Demographics of population covered (age, gender)
Comorbidities and risk factors
Inclusion/exclusion criteria†
Type and details of healthcare facilities
Microbiology Specimen type and carriers tested
Duplicates policy
Clinical value of the sample
Pathogens, sources and acquisition
Microbiological methods for the identification and characterization of mechanisms of
resistanceAntibiotics tested and resistance mechanisms
Methodology and indicators
used
Clinical criteria and microbiological definitions used, Structure, process and outcome
indicators reported, Measurement frequency of relevant indicators, Reporting of source
data (volunteer/compulsory)
Data analysis, reporting and
dissemination
Source of data and data collection systems, Quality assessments*, Stratification of reported
data, Reporting type and frequency, Dissemination of data*
*Surveillance systems.
†Epidemiological studies.
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deﬁnitions, methods and quality assessment, as well as
the infections and microorganisms/resistances.
AMR surveillance has traditionally focused on either
the percentage of particular pathogens that are resistant
to certain antimicrobial agents and/or rates of isolation
of relevant resistant bacteria. However, some potentially
important aspects, such as the speciﬁc populations or
patients in which these infections occur, types of infec-
tion and their outcomes have not usually been consid-
ered because of the additional complexity and resources
needed. Nevertheless, these are key aspects for inform-
ing management decisions about the prioritisation and
provision of resources required to address the problem
and determining the most urgent areas for research.
Furthermore, the way that national surveillance systems
are conceptually set up at present may be too slow to
provide useful information for immediate global action
in situations of the emergence of new resistant patho-
gens or the further spread of previously known ones, as
is shown by the recent spread of carbapenemase-
producing Enterobacteriaceae in many European coun-
tries and across borders.12 Therefore, speciﬁc evaluation
of AMR surveillance systems and the gaps that exist is
required in order to detect areas for improvement.
The objectives of the COMBACTE-MAGNET consor-
tium, funded by the European Union and, in kind, by
the European Federation of Pharmaceutical Industries
Association (EFPIA) through the Innovative Medicines
Initiative, include building a European network by
engaging representatives from the major EU ﬁnanced
projects, stakeholder experts and industry in order to
develop a consensus programme and a homogeneous
approach to current and future epidemiological surveil-
lance strategies in Europe. The SUSPIRE project will
work to achieve this objective.
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